Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Plasma cell 1 Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1 Genetic Predisposition to Disease 1

Interventions

Dexamethasone 479 Lenalidomide 297 Cyclophosphamide 271 Bortezomib 267 Melphalan 212 Calcium Dobesilate 189 fludarabine phosphate 121 daratumumab 121 Peripheral Blood Stem Cell Transplantation 101 fludarabine 99 carfilzomib 98 Thalidomide 94 pomalidomide 92 Filgrastim 92 Whole-Body Irradiation 88 Mycophenolic Acid 88 Busulfan 80 Tacrolimus 75 Granulocyte Colony-Stimulating Factor 72 dexamethasone acetate 65 ixazomib 62 Cyclosporine 59 dexamethasone 21-phosphate 56 Antilymphocyte Serum 51 auricularum 50 isatuximab 44 Radiotherapy 41 Etoposide 40 Stem Cell Transplantation 39 Methotrexate 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sequence Analysis, DNA × Plasma cell × Clear all

NCT05331313 2022-04-15

MMSPORADGEN

Hospices Civils de Lyon

Multiple Myeloma, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡